Compare QQQX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QQQX | TYRA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2021 |
| Metric | QQQX | TYRA |
|---|---|---|
| Price | $25.57 | $20.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $47.45 |
| AVG Volume (30 Days) | 102.6K | ★ 530.2K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.35 | $18.25 |
| 52 Week High | $31.87 | $40.65 |
| Indicator | QQQX | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 23.15 | 43.93 |
| Support Level | $25.35 | $18.46 |
| Resistance Level | $31.11 | $22.69 |
| Average True Range (ATR) | 0.80 | 1.15 |
| MACD | -0.34 | -0.08 |
| Stochastic Oscillator | 2.09 | 19.25 |
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets (as defined below) in a diversified equity portfolio made up of securities comprising the S&P 500 Index (or securities that have economic characteristics that are similar to those securities comprising the S&P 500 Index) that seeks to substantially replicate price movements of the S&P 500 Index and is designed to support the Fund's option strategy.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.